Identification of potential drug targets for erectile dysfunction with single-cell RNA sequencing: A Mendelian...

Area of Science:

• Genetics and Bioinformatics
• Pharmacology
• Urology

Background:

• Erectile dysfunction (ED) treatment is limited by a lack of well-defined therapeutic targets beyond phosphodiesterase 5 inhibitors (PDE5i).
• A significant patient subset shows poor response to existing ED therapies, necessitating novel treatment strategies.

Purpose of the Study:

• To identify novel therapeutic targets for erectile dysfunction (ED) using a Mendelian randomization (MR) approach.
• To validate the therapeutic potential of identified targets through drug prediction and molecular docking.

Main Methods:

• Mendelian randomization (MR) analysis utilizing cis-expression quantitative trait loci (cis-eQTL) data and large-scale ED summary statistics.
• Co-localization analysis to confirm shared genetic influence on ED risk and gene expression.
• Drug prediction, molecular docking, and single-cell RNA sequencing (scRNA-seq) for target validation and cell-type identification.

Main Results:

• Two significant drug targets for ED were identified and validated across independent cohorts.
• Co-localization analysis confirmed the association of identified single nucleotide polymorphisms (SNPs) with both ED risk and gene expression.
• Molecular docking demonstrated strong binding affinities, and scRNA-seq revealed predominant expression in endothelial cells (ECs), Schwann cells (SWCs), and smooth muscle cells (SMCs).

Conclusions:

• Two promising novel targets for ED treatment have been identified.
• Further research focusing on ECs and SMCs is warranted to advance drug development for improved ED outcomes.